ESMO: European Society for Medical Oncology

The latest news from ESMO
  1. New measure of tumour mutational burden based on genomic regions unlikely to undergo loss

  2. Findings from a phase II clinical study of combined PD1, BRAF and MEK inhibition

  3. Evidence for efficacy is based on the results from the KEYNOTE-091 study

  4. Findings from a large cohort of patients with advanced non-small cell lung cancer demonstrate substantially different gain in survival by age

  5. New indication concerns the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with docetaxel and androgen deprivation therapy